Switch theme
Sign up to access all valuation multiples
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
1991
3.0K+
LTM Revenue $688M
LTM EBITDA -$148M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OPKO Health has a last 12-month revenue (LTM) of $688M and a last 12-month EBITDA of -$148M.
In the most recent fiscal year, OPKO Health achieved revenue of $713M and an EBITDA of $135M.
OPKO Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OPKO Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $688M | XXX | $713M | XXX | XXX | XXX |
| Gross Profit | $274M | XXX | $219M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 31% | XXX | XXX | XXX |
| EBITDA | -$148M | XXX | $135M | XXX | XXX | XXX |
| EBITDA Margin | -22% | XXX | 19% | XXX | XXX | XXX |
| EBIT | -$181M | XXX | -$274M | XXX | XXX | XXX |
| EBIT Margin | -26% | XXX | -38% | XXX | XXX | XXX |
| Net Profit | -$132M | XXX | -$53.2M | XXX | XXX | XXX |
| Net Margin | -19% | XXX | -7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $5.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, OPKO Health's stock price is $1.
OPKO Health has current market cap of $1.1B, and EV of $1.1B.
See OPKO Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.1B | XXX | XXX | XXX | XXX | $-0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, OPKO Health has market cap of $1.1B and EV of $1.1B.
OPKO Health's trades at 1.6x EV/Revenue multiple, and 8.4x EV/EBITDA.
Equity research analysts estimate OPKO Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OPKO Health has a P/E ratio of -8.2x.
See valuation multiples for OPKO Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | -7.7x | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBIT | -6.3x | XXX | -4.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.2x | XXX | -20.3x | XXX | XXX | XXX |
| EV/FCF | -32.5x | XXX | -5.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOPKO Health's last 12 month revenue growth is -2%
OPKO Health's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
OPKO Health's rule of 40 is -10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OPKO Health's rule of X is -27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OPKO Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | -22% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | -41% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -10% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -27% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OPKO Health acquired XXX companies to date.
Last acquisition by OPKO Health was XXXXXXXX, XXXXX XXXXX XXXXXX . OPKO Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OPKO Health founded? | OPKO Health was founded in 1991. |
| Where is OPKO Health headquartered? | OPKO Health is headquartered in United States of America. |
| How many employees does OPKO Health have? | As of today, OPKO Health has 3.0K+ employees. |
| Who is the CEO of OPKO Health? | OPKO Health's CEO is Dr. Phillip Frost, M.D.. |
| Is OPKO Health publicy listed? | Yes, OPKO Health is a public company listed on NAS. |
| What is the stock symbol of OPKO Health? | OPKO Health trades under OPK ticker. |
| When did OPKO Health go public? | OPKO Health went public in 1995. |
| Who are competitors of OPKO Health? | Similar companies to OPKO Health include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of OPKO Health? | OPKO Health's current market cap is $1.1B |
| What is the current revenue of OPKO Health? | OPKO Health's last 12 months revenue is $688M. |
| What is the current revenue growth of OPKO Health? | OPKO Health revenue growth (NTM/LTM) is -2%. |
| What is the current EV/Revenue multiple of OPKO Health? | Current revenue multiple of OPKO Health is 1.7x. |
| Is OPKO Health profitable? | Yes, OPKO Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OPKO Health? | OPKO Health's last 12 months EBITDA is -$148M. |
| What is OPKO Health's EBITDA margin? | OPKO Health's last 12 months EBITDA margin is -22%. |
| What is the current EV/EBITDA multiple of OPKO Health? | Current EBITDA multiple of OPKO Health is -7.7x. |
| What is the current FCF of OPKO Health? | OPKO Health's last 12 months FCF is -$35.1M. |
| What is OPKO Health's FCF margin? | OPKO Health's last 12 months FCF margin is -5%. |
| What is the current EV/FCF multiple of OPKO Health? | Current FCF multiple of OPKO Health is -32.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
